共 406 条
[1]
Geissler EK(2008)mTOR, cancer, and transplantation Am J Transplant 8 2212-2218
[2]
Schlitt HJ(2007)Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy Transplant Proc 39 2937-2950
[3]
Thomas G(1998)Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 335-340
[4]
Chapman JR(2005)Sirolimus for Kaposi’s sarcoma in renal-transplant recipients N Engl J Med 352 1317-1323
[5]
Valantine H(2009)The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer Br J Cancer 100 971-978
[6]
Albanell J(2010)Targeting mTOR pathway: a new concept in cancer therapy Indian J Med Paediatr Oncol 31 132-136
[7]
Arns WA(2011)Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy J Clin Invest 121 1231-1241
[8]
Campistol JM(2012)Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus Onco Targets Ther 5 217-224
[9]
Eisen H(2003)Tuberous sclerosis: from tubers to mTOR Ann Hum Genet 67 87-96
[10]
Frigerio M(2006)Everolimus in clinical practice–renal transplantation Nephrol Dial Transplant 21 iii18-iii23